Peptide therapy 'what's next': hype versus hard evidence

What did @daviddemesquita actually say?

The claim here is that "one of the biggest peptide companies in the world has officially shut down" and that the shutdown, though labeled voluntary, was likely forced. He then raises a pointed question: is this a sign the FDA is gearing up for another enforcement sweep, comparing it to raids that hit six peptide companies roughly a year and a half ago. He closes with a reference to something called a "Ureida," which is almost certainly a mispronunciation of "URADA" or more likely "URADA-style action," possibly referencing a broader regulatory crackdown framework.

To be clear, no specific company is named in the video. That makes this genuinely difficult to fact-check with precision. Without naming the company, viewers have no way to verify the claim independently, which is a problem worth noting from the start.

Does the science back this up?

There is no "science" to evaluate here in the traditional sense. This is a regulatory and market claim, not a clinical one. But the regulatory history is real and documented.

The FDA has been increasingly aggressive toward compounding pharmacies and peptide suppliers operating in gray-market territory. In 2022 and 2023, the FDA issued warning letters and conducted inspections targeting facilities distributing unapproved peptides like BPC-157, TB-500, and CJC-1295. The FDA's position is that many of these peptides are not eligible for compounding under the Federal Food, Drug, and Cosmetic Act because they are not approved drug substances on the 503A or 503B lists.

The 2023 FDA guidance explicitly flagged several peptides as having "significant safety concerns" or being "demonstrably difficult to compound," effectively cutting off a legal pathway for many compounders. Companies that shut down after such guidance often do so because continuing would expose them to seizure, injunction, or criminal referral. Calling that "voluntary" is, as the creator implies, a stretch.

What did they get wrong (or right)?

He gets credit for skepticism. When a heavily regulated business announces a "voluntary" closure, the instinct to question the framing is reasonable, and in this industry, historically accurate. The 2022-2023 enforcement actions against peptide suppliers were not subtle. The FDA does not typically telegraph raids, but it does issue warning letters before escalating, and companies that ignore them tend to disappear quickly or quietly.

What he gets wrong, or at least leaves dangerously vague, is the reference to "Ureida." It is unclear what regulatory mechanism he is describing. If he means a coordinated multi-agency action similar to Operation Cyber Shield or other FDA-DEA joint operations, that is a real possibility worth discussing clearly. Vague references to unnamed enforcement actions in a high-view TikTok video do not inform viewers. They create anxiety without context.

He also does not name the company. A claim that "one of the biggest peptide companies in the world" has shut down is significant. Without a name, it is an unverifiable assertion, not a news report.

What should you actually know?

The peptide compounding space has been under sustained FDA scrutiny since at least 2021, when the agency began reviewing which bulk drug substances could legally be used in compounding. Several peptides popular in biohacking communities, including BPC-157 and TB-500, have not been approved by the FDA and exist in a legally precarious position for compounders.

If you are currently using compounded peptides through a telehealth provider, the relevant question is not whether a specific company shut down. The relevant question is whether your provider sources from an FDA-registered 503B outsourcing facility and whether the peptides you are prescribed are on a legally permissible compounding list. Those are concrete things you can ask.

Enforcement in this space tends to move in waves, and the creator is not wrong that a high-profile closure can signal broader regulatory attention. But "the FDA is coming" is not a clinical fact. It is a market observation, and it should be treated as one.